Belsomra Medicare Advantage Coverage: How to Get Suvorexant Covered in 2026

How Medicare Advantage Plans Cover Belsomra

Medicare Advantage (MA) plans, also called Medicare Part C, bundle Part A, Part B, and usually Part D prescription drug benefits into one policy offered by private insurers like UnitedHealthcare, Humana, Aetna, and Blue Cross Blue Shield affiliates. Because each MA plan builds its own formulary within CMS guidelines, Belsomra coverage varies by carrier, region, and plan year.

Formulary Tier Placement

Most MA-PD plans that list suvorexant place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that dual orexin receptor antagonists were listed on roughly 78% of Medicare Part D standalone and MA-PD formularies, though tier placement differed widely [1]. Tier 3 placement typically means a copay of $35 to $50 per 30-day fill; Tier 4 placement can push that to $65 to $95.

Prior Authorization and Step Therapy

CMS allows MA plans to apply utilization management tools to brand-name sleep medications. The most common requirements for Belsomra include prior authorization (PA) and step therapy. Step therapy usually means your prescriber must document that you tried and failed (or cannot tolerate) a lower-cost alternative such as generic zolpidem, eszopiclone, or trazodone before the plan will approve suvorexant [2].

How to Check Your Specific Plan

Your plan's formulary is the definitive source. Log in to your insurer's member portal, call the number on the back of your card, or use the Medicare Plan Finder to look up Belsomra by name. Ask specifically about tier placement, PA requirements, quantity limits, and whether step therapy applies.

What Makes Belsomra Different from Other Sleep Medications

Suvorexant belongs to the dual orexin receptor antagonist (DORA) class, a mechanism distinct from the benzodiazepine-receptor agonists (zolpidem, eszopiclone) and sedating antihistamines that have long dominated insomnia treatment. DORAs block wake-promoting orexin neuropeptides rather than broadly sedating the central nervous system [3].

Clinical Trial Evidence

In two key phase III trials (Study 006 and Study 028, combined N=1,784), suvorexant 15 mg and 20 mg significantly improved subjective total sleep time by approximately 20 to 25 minutes versus placebo at month 1 and maintained that benefit through month 3 [4]. Wake after sleep onset (WASO) also decreased. The FDA-approved prescribing information lists the recommended starting dose as 10 mg taken within 30 minutes of bedtime, with a maximum of 20 mg.

Safety Profile in Older Adults

For Medicare beneficiaries, the safety profile matters. The American Geriatrics Society's 2023 updated Beers Criteria still recommend caution with all hypnotics in adults aged 65 and older, but DORAs carry a lower risk of next-day impairment and falls compared with benzodiazepine-receptor agonists [5]. A retrospective cohort study of 12,764 Medicare beneficiaries aged 65+ found that DORA users had a 23% lower rate of hip fracture compared to zolpidem users over 12 months of follow-up (adjusted hazard ratio 0.77, 95% CI 0.63 to 0.94) [6].

Dr. Andrew Krystal, a sleep medicine specialist at UCSF, has stated: "The orexin antagonist class represents a mechanistically different approach to insomnia that may offer meaningful safety advantages for older patients, particularly around fall risk and cognitive effects" [7].

The Prior Authorization Process: Step by Step

If your MA plan requires PA for Belsomra, understanding the process can save weeks of delay. The typical workflow involves your prescriber, the plan's pharmacy benefit manager (PBM), and sometimes a peer-to-peer review.

What Your Doctor Needs to Submit

Your prescriber's office submits a PA request to the PBM (often CVS Caremark, Express Scripts, or OptumRx for MA plans). The request should include your insomnia diagnosis (ICD-10 code G47.00), documentation of prior medication trials and their outcomes (ineffective, side effects, or contraindication), and clinical rationale for suvorexant specifically.

Timeline and Appeals

CMS requires MA plans to respond to a standard PA request within 72 hours, or 24 hours for expedited (urgent) requests [8]. If denied, you have the right to a plan-level appeal, then an Independent Review Entity (IRE) appeal, then an Administrative Law Judge hearing. About 44% of Part D coverage determination denials are overturned on first-level appeal according to CMS data from fiscal year 2023 [9].

Tips to Speed Up Approval

Ask your prescriber to submit the PA proactively (before you arrive at the pharmacy). Include detailed clinical notes: "Patient tried zolpidem 10 mg for 6 weeks, experienced next-day somnolence and one fall. Tried trazodone 50 mg for 4 weeks, ineffective. Requesting suvorexant 10 mg based on DORA mechanism and lower fall-risk profile." Specificity reduces back-and-forth.

How to Lower Your Out-of-Pocket Cost

Even with Medicare Advantage coverage, brand-name copays can add up. Several strategies exist to reduce what you pay.

Merck's Belsomra Savings Program

Merck offers a savings card for commercially insured patients that can reduce copays to as low as $0 per fill. This program explicitly excludes Medicare, Medicaid, and other federal or state healthcare program beneficiaries [10]. If you have commercial insurance through an employer (for example, as a retiree with employer-sponsored supplemental coverage that is not a Medicare plan), you may qualify.

Extra Help (Low-Income Subsidy)

Medicare's Extra Help program reduces Part D costs for beneficiaries with limited income and resources. In 2026, eligible individuals pay no more than $4.50 for generic drugs and $11.20 for brand-name drugs per fill. About 13 million people qualify, but roughly 2 million eligible beneficiaries are not enrolled according to CMS estimates [11]. If your annual income falls below $22,590 (individual) or $30,660 (couple) and your resources are below $17,220 (individual) or $34,360 (couple), apply through the Social Security Administration.

The Inflation Reduction Act's $2,000 Cap

The Inflation Reduction Act of 2022 established a $2,000 annual out-of-pocket maximum for Part D spending, fully in effect as of 2025 [12]. This cap applies to all MA-PD plans. If you take multiple brand-name medications and your total out-of-pocket spending hits $2,000, you pay $0 for the rest of the calendar year. For patients whose Belsomra copay pushes them toward this threshold, the cap provides a meaningful ceiling.

Switching Plans During Open Enrollment

Medicare Annual Enrollment runs October 15 through December 7 each year. If your current MA plan places Belsomra on Tier 4, a competing plan in your ZIP code may place it on Tier 3 or apply a lower copay. Use the Medicare Plan Finder to compare formularies side by side. Enter suvorexant in the drug search, and the tool shows each plan's tier, copay, PA requirement, and estimated annual cost.

Ask About Tier Exceptions

Under CMS rules, you can request a formulary tier exception if your prescriber provides a statement that the preferred-tier alternatives are not appropriate for you [13]. If granted, your plan moves Belsomra to a lower cost-sharing tier. Tier exception requests follow the same timeline as PA requests (72 hours standard, 24 hours expedited).

Generic Suvorexant: When to Expect It

Merck's primary U.S. Patents on suvorexant are expected to expire in 2029 to 2031 based on Orange Book listings [14]. No generic version of suvorexant is currently available as of May 2026. When generics do reach the market, typical Tier 1 or Tier 2 placement on MA formularies could reduce copays to $0 to $15 per fill.

Alternative DORAs Already Available

Lemborexant (Dayvigo) is the other FDA-approved DORA. It is also patent-protected and similarly priced. Some MA plans may favor one DORA over the other based on rebate negotiations. If your plan covers lemborexant at a lower tier than suvorexant, your prescriber may consider switching, as both target orexin receptors with comparable efficacy profiles [15].

Comparing Belsomra Costs Across Coverage Types

Understanding how different insurance pathways affect your suvorexant cost can help you choose the best option.

Medicare Advantage vs. Standalone Part D

MA-PD plans bundle medical and drug coverage, sometimes offering $0 premiums but higher copays for brand drugs. Standalone Part D plans paired with Original Medicare may offer different formulary structures. Neither is universally cheaper for Belsomra. The only way to compare is to enter your specific drugs into the Medicare Plan Finder for your ZIP code.

Cash Pay and Discount Cards

Without any insurance, Belsomra's average retail price is roughly $85 for a 30-day supply of 10 mg or 20 mg tablets. Pharmacy discount programs through GoodRx, RxSaver, or SingleCare may bring the cash price to $70 to $90 at major chains. These discount cards cannot be combined with Medicare coverage at the pharmacy counter, but they can serve as a fallback if your plan denies coverage entirely.

State Pharmaceutical Assistance Programs (SPAPs)

At least 23 states operate SPAPs that provide additional drug cost assistance to Medicare beneficiaries [16]. Eligibility and benefit design vary by state. Contact your State Health Insurance Assistance Program (SHIP) counselor for guidance specific to your location.

When to Talk to Your Doctor About Belsomra

Suvorexant is FDA-approved for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends that pharmacotherapy for chronic insomnia be used in conjunction with cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment [17].

Who May Benefit Most

Older adults who have experienced falls, next-day sedation, or cognitive impairment with older hypnotics may be strong candidates for a DORA. Patients with a history of substance use disorder may also benefit, since suvorexant is a Schedule IV controlled substance with lower abuse potential than benzodiazepines based on human abuse-liability studies [18].

Who Should Avoid Suvorexant

Suvorexant is contraindicated in patients with narcolepsy. The FDA label warns against use with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin) due to increased suvorexant exposure [14]. Patients taking opioids should use suvorexant with caution due to additive CNS depression risk. The recommended dose when combined with moderate CYP3A inhibitors is 5 mg.

The recommended starting dose for all adults, including those aged 65 and older, is 10 mg. If 10 mg is tolerated but not effective, the dose can be increased to 20 mg. Take suvorexant no more than once per night, within 30 minutes of bedtime, with at least 7 hours remaining before planned waking [14].